Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…
Mexico Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how ICR is developing clinical studies for allopathic, biotech, medtech, and herbal medicine companies. Only 15 years ago, the Mexican clinical…
Infinite Clinical Research We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by up to 30% when compared to the United States and Europe. In your opinion, what is the most common reason…
See our Cookie Privacy Policy Here